Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Short-term Investments (2020 - 2025)

Tarsus Pharmaceuticals has reported Short-term Investments over the past 6 years, most recently at $233.6 million for Q4 2025.

  • Quarterly results put Short-term Investments at $233.6 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $233.6 million (changed N/A YoY), and the annual figure for FY2025 was $233.6 million, changed.
  • Short-term Investments for Q4 2025 was $233.6 million at Tarsus Pharmaceuticals, down from $289.1 million in the prior quarter.
  • Over the last five years, Short-term Investments for TARS hit a ceiling of $289.1 million in Q3 2025 and a floor of $20000.0 in Q1 2021.
  • Median Short-term Investments over the past 5 years was $120.0 million (2023), compared with a mean of $116.3 million.
  • Peak annual rise in Short-term Investments hit 46368.04% in 2023, while the deepest fall reached 98.28% in 2023.
  • Tarsus Pharmaceuticals' Short-term Investments stood at $483000.0 in 2021, then soared by 29996.48% to $145.4 million in 2022, then tumbled by 98.28% to $2.5 million in 2023, then soared by 5540.96% to $140.7 million in 2024, then skyrocketed by 66.0% to $233.6 million in 2025.
  • The last three reported values for Short-term Investments were $233.6 million (Q4 2025), $289.1 million (Q3 2025), and $284.5 million (Q2 2025) per Business Quant data.